Ucb
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Website
www.ucbonward.comRevenue
<$5 MillionIndustry
ZI Rank: 1
About Ucb
Ucb Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ucb your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Ucb had a recent Job posting/layoffs
Check if Ucb has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Ucb launches new products
Check out if Ucb is spiking on competitors!
Ucb, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Ucb
Earning: See what the market has to say on Ucb recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Ucb has new funding data
Recommended Actions
Reach out to Masked Content who joined Ucb as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Ucb is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ucb is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ucb.
Ucb Tech Stack
A closer look at the technologies used by Ucb
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ucb
UCB, Inc. specializes in immunology therapies, focusing on the treatment of various conditions including active psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, moderate-to-severe plaque psoriasis, and hidradenitis suppurativa. Their product, BIMZELX, is the first approved dual inhibitor of IL-17A and IL-17F, d... Read More
